Jubilant Pharmova has reported total income of Rs.1586.47 crores during the period ended March 31, 2021 as compared to Rs.1774.93 crores during the period ended December 31, 2020. The company reported total income Rs.1585.84 crores during the period ended March 31, 2020.

The company has posted net profit of Rs.213.90 crores for the period ended March 31, 2021 as against net profit of Rs.309.93 crores for the period ended December 31, 2020. The company posted net profit of Rs.260.49 crores for the period ended March 31, 2020.

Jubilant Pharmova has reported total income of Rs.6116.18 crores during the 12 months period ended March 31, 2021 as compared to Rs.6013.20 crores during the 12 months period ended March 31, 2020.

The company has posted net profit of Rs.835.87 crores for the 12 months period ended March 31, 2021 as against net profit of Rs.898.24 crores for the 12 months period ended March 31, 2020.

Commenting on the Company's performance, Shyam S Bhartia, Chairman and Hari S Bhartia, CoChairman & Managing Director, Jubilant Pharmova said: "With the demerger of LSI business into Jubilant Ingrevia effective February 1, 2021, the Company's consolidated results for Q4'FY21 include only one month of LSI business and consolidated results for FY21 include only ten months of LSI business.

For FY21 our continuing operations, despite COVID-19 challenges, revenues were stable due to a diverse range of businesses. CDMO and Generics grew though we saw impact on radiopharma and had production impact at the Nanjangud API plant.

Specialty Pharma segment especially radiopharma was impacted due to COVID-19 and competition in radiopharma. We continue to maintain majority market share in our products and have long term contracts in place. In radiopharmaceuticals, we are expanding our product pipeline with strategic partnerships and have begun to execute a detailed turnaround plan of radiopharmacy business. CMO and Generics delivered strong growth and we plan to expand capacity in CMO and enhance number and complexity of products under development in Generics.

Contract Research and Development Services business witnessed strong year-on-year growth in revenues led by healthy demand from customers. We are doubling our chemistry research capacity that should commission by Q2'FY22.

Despite COVID-19 related lockdowns, we have been able to ensure continuity in most of our manufacturing operations across all business segments while at the same time ensuring safety of our employees. I take this opportunity to thank all our employees who have worked tirelessly across all our plants and offices to ensure continuity in company's operations, while continuing to serve our global customers."